Immuno-oncology Treatment Devices and Drugs Segmentation
Product (Drugs, Devices)
Based on product, the drugs segment is expected to garner a lucrative share of 53.7% in the immuno-oncology treatment devices and drugs market by the end of 2037. The dominance of the segment is highly attributed to its continuous and widespread usage across all nations. For instance, in 2023, a clinical study by AHRQ found that the checkpoint inhibitors can save hospitalization costs by USD 9,000 per patient annually. Besides, the U.S. FDA’s accelerated approvals, i.e., 8 new indications from 2023 to 2025, expanded access to 26% of patients, further propelling the segment’s dominance.
End user (Hospitals, Specialty Clinics, Research Institutes)
Based on the end user, the hospitals segment is projected to grow at a considerable rate, with a share of 45.3% in the immuno-oncology treatment devices and drugs market in the assessed timeline. Hospitals play a critical role in cancer treatment owing to the presence of advanced equipment in these settings. As a result, the segment is subject to growth in support of coverage for inpatient immunotherapy procedures, which increased hospital adoption by 20% as of the CMS 2024 report. Besides, more than 58% of hospitals in the U.S. comprise dedicated immune oncology units, further reflecting a positive outlook for the segment’s growth.
Our in-depth analysis of the immuno-oncology treatment devices and drugs market includes the following segments:
|
Product |
|
|
Application |
|
|
End user |
|
